Intellia Therapeutics Inc To Discuss Interim Clinical Data from Ongoing First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema Transcript
Good morning, and welcome to the Intellia Therapeutics NTLA-2002 Interim Clinical Data Update Event. My name is Drew, and I will be your conference operator today. Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. (Operator Instructions)
I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you, operator, and good morning, everyone. I'm pleased to welcome you to Intellia's investor call, featuring updated interim data from the Phase I portion of the ongoing NTLA-2002 Phase I/II study. On Sunday, Intellia issued a press release detailing these results, which are presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress held this past week in Hamburg, Germany and virtually.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
